Showing results (91-100 of 114) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2017
Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid LeukemiaJe-Hwan Lee, Hawk Kim, Young-Don Joo, et al.
The Korean Journal of Internal Medicine|December 14, 2017
No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndromeSang Kyun Sohn, Joon Ho Moon, In Hee Lee, et al.
Annals of Hematology|March 28, 2014
Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry studySukjoong Oh, Dong Hoe Koo, Min-Jung Kwon, et al.
Annals of Hematology|October 12, 2012
KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangementHee-Jin Kim, Hee Kyung Ahn, Chul Won Jung, et al.
Transfusion|March 13, 2015
Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overloadIl-Hwan Kim, Joon-Ho Moon, Sung-Nam Lim, et al.
Leukemia Research|February 1, 2022
The association of genetic alterations with response rate in newly diagnosed chronic myeloid leukemia patientsHyunkyung Park, Sungbong Kang, Inho Kim, et al.
Leukemia & Lymphoma|May 8, 2015
Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patientsJoon Seong Park, Sung-Eun Lee, Seong Hyun Jeong, et al.
Haematologica|February 19, 2016
Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID studySung-Eun Lee, Soo Young Choi, Hye-Young Song, et al.
Annals of Hematology|April 6, 2013
Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemiaSang Min Lee, Won Sik Lee, Ho Jin Shin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2017
Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid LeukemiaJae-Yong Kwak, Sung-Hyun Kim, Suk Joong Oh, et al.
Pageof 12